Doxorubicin Hydrochloride Liposome Injection, Suspension, Liposomal
Product Images NDC 0338-0080

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride Liposome (NDC 0338-0080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxorubicin HCl Structural Formula (Image 01)

Chemical structure of Doxorubicin Hydrochloride, the active ingredient in Doxorubicin Hydrochloride Liposome injection, 2 mg/mL by Baxter Healthcare Company. The diagram shows the molecular arrangement, including the characteristic anthracycline ring system and the hydrochloride salt form.*

FDA Label Image

Mpeg-dspe Structural Formula (Image 02)

Chemical structure diagram representing the molecular formula of the active ingredient in Doxorubicin Hydrochloride Liposome injection suspension, liposomal form, 2 mg/mL strength by Baxter Healthcare Company. The structure includes a repeating polyethylene glycol chain (n ≈ 45), phosphate groups, and lipid components characteristic of liposomal formulations.*

FDA Label Image

Hspc Structural Formula (Image 03)

Chemical structure diagram of Doxorubicin Hydrochloride Liposome showing the molecular composition and arrangement relevant to the liposomal formulation.*

FDA Label Image

Stealth Liposome Representation (Image 04)

An illustration depicting the structure of doxorubicin hydrochloride liposome, showing the aqueous core containing trapped doxorubicin HCl, surrounded by a liposomal bilayer, and an outer coating labeled as MPEG-DSPE.*

FDA Label Image

Figure 1 (Time to Progressopm Kaplan-Meier Curve)

A Kaplan-Meier survival curve showing the percentage of subjects progression-free over time (months) comparing two treatments: Doxorubicin HCl plus Bortezomib versus Bortezomib alone. The graph includes censored data points and a table of the number of subjects at risk over time for each treatment group. Statistical results including a p-value less than 0.0001 and a hazard ratio with confidence intervals are shown.*

FDA Label Image

Representative Doxorubicin Container Label 0338-0080-01 (Image 06)

Label for Doxorubicin Hydrochloride liposome injection, 20 mg in 10 mL (2 mg/mL) single-dose vial. The label includes a warning that it is a liposomal formulation and not to substitute for doxorubicin hydrochloride. It is indicated for intravenous infusion only, with directions to discard unused portions. Manufactured for Baxter Healthcare Corporation.*

FDA Label Image

Representative Doxorubicin Carton Label 0338-0080-01 (1 of 4)

Packaging label for Doxorubicin Hydrochloride Liposome injection, 20 mg in 10 mL (2 mg/mL) single-dose vial by Baxter Healthcare Company. The label highlights the liposomal formulation and indicates it is for intravenous infusion only. Storage instructions specify refrigeration at 2°-8°C (36°-46°F) without freezing. The label also includes product NDC 0338-0080-01 and a barcode.*

FDA Label Image

Representative Doxorubicin Carton Label 0338-0080-01 (2 of 4)

Packaging label for Doxorubicin Hydrochloride liposome injection 2 mg/mL, a liposomal injection suspension. The label emphasizes the liposomal formulation and cautions not to substitute for Doxorubicin Hydrochloride. It is manufactured for Baxter Healthcare Corporation. The detailed composition includes doxorubicin hydrochloride and various liposome carriers. The label also features a barcode and fields for serial number, expiration date, and lot number.*

FDA Label Image

Representative Doxorubicin Carton Label 0338-0080-01 (3 of 4)

Packaging label for Doxorubicin Hydrochloride Liposome Injection, 2 mg/mL strength, presented as 20 mg in 10 mL single-dose vial. Liposomal formulation, for intravenous infusion only after dilution. Manufactured by Baxter Healthcare Company. Label includes storage instructions and dilution guidance using 5% Dextrose Injection, USP.*

FDA Label Image

Representative Doxorubicin Carton Label 0338-0080-01 (4 of 4)

Packaging label for Doxorubicin Hydrochloride liposome injection, 2 mg/mL, a liposomal formulation for intravenous use. The label shows the proprietary and generic name, warns not to substitute for non-liposomal doxorubicin, and lists the manufacturer as Baxter Healthcare Corporation, Deerfield, IL. Ingredients and formulation details are included on the side panel, along with product codes and trademark information.*

FDA Label Image

Representative Doxorubicin Container Label 0338-0086-01 (Image 11)

Label for Doxorubicin Hydrochloride liposome injection, 50 mg in 25 mL (2 mg/mL) single-dose vial. The injectable suspension is for intravenous infusion only and is marked as cytotoxic. It states refrigeration requirements and is manufactured for Baxter Healthcare Corporation, Deerfield, IL.*

FDA Label Image

Representative Doxorubicin Carton Label 0338-0086-01 (1 of 4)

Packaging label for Doxorubicin Hydrochloride liposome injection, 50 mg in 25 mL (2 mg/mL) in a single-dose vial by Baxter Healthcare Company. The label indicates it is for intravenous infusion only, requiring refrigeration at 2°-8°C and warns not to substitute for doxorubicin hydrochloride. It is marked cytotoxic and prescription only.*

FDA Label Image

Representative Doxorubicin Carton Label 0338-0086-01 (2 of 4)

Label for Doxorubicin Hydrochloride liposome injection 2 mg/mL, a liposomal suspension for intravenous use. Label features the proprietary name, a warning in red stating "Liposomal Formulation - Do Not Substitute for Doxorubicin Hydrochloride," manufacturer information for Baxter Healthcare Corporation, and a detailed list of active ingredients and excipients. The label includes coding information such as GTIN and lot details.*

FDA Label Image

Representative Doxorubicin Carton Label 0338-0086-01 (3 of 4)

Packaging label for Doxorubicin Hydrochloride liposome injection, 50 mg in 25 mL (2 mg/mL) single-dose vial by Baxter Healthcare Company. Label includes warnings for intravenous infusion only after dilution, refrigeration requirements, cytotoxic designation, and notes that it is a liposomal formulation. Contains a barcode and instructions to use 5% dextrose injection when diluting.*

FDA Label Image

Representative Doxorubicin Carton Label 0338-0086-01 (4 of 4)

Packaging label for Doxorubicin Hydrochloride liposome injection, 2 mg/mL, in suspension liposomal dosage form for intravenous use. Manufactured by Baxter Healthcare Corporation, this label includes NDC 0338-0086-01 and details the liposomal formulation, ingredients, and storage information. The label features a red warning area indicating this is a liposomal formulation and not to substitute for regular doxorubicin hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.